Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights

Contributed by: Business Wire

Logo

Tags

Biotechnology

Professional Services

Health

Pharmaceutical

Research

Genetics

Environment

Science

Clinical Trials

Finance

Sustainability

Strong FY2025 Financial and Sustainability Results

More Like This

Chiesi Group's 2023 Revenue Surpasses €3 Billion Mark, Reflecting 10% Growth Year-on-Year (+12% @CER), Underlining Commitment to Innovative, Sustainable Practices

Chiesi Global Rare Diseases Highlights Continued Commitment to Rare Disease Community at the International Congress of Inborn Errors of Metabolism (ICIEM) 2025

Maria Paola Chiesi is appointed Chair of Chiesi Board of Directors, the first woman in this role; aims to reinforce sustainability as an integral and enduring pillar of the Group’s strategy

Chiesi Group Announces New Chair and Vice Chair

Chiesi Group's new Biotech Center of Excellence brings the future of medicine to Parma

PR Newswire associated0

Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030

Alfasigma Reports Solid Performance in 2025 Supported by Double-Digit Revenue Growth in key strategic brands in Immunology (+17%1), Gastroenterology (+15%), Vascular (+10%), and Consumer Healthcare expansion portfolio in international markets

Chiesi Group Forges Alliance with Karolinska Institutet to Tackle Urgent Health Challenges

For the First Time, Ferring Reports Revenue of Over €2.5 Billion in 2025